101 related articles for article (PubMed ID: 19212683)
41. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
[TBL] [Abstract][Full Text] [Related]
42. [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Abe S; Kojima M; Tamura H; Kurihara H; Kitago M; Kobayashi T; Nakamura T; Ogihara T
Gan To Kagaku Ryoho; 2003 Jul; 30(7):963-70. PubMed ID: 12894711
[TBL] [Abstract][Full Text] [Related]
43. Pathological Complete Response by S-1 Chemotherapy in Advanced Gastric Cancer.
Namikawa T; Ishida N; Tsuda S; Fujisawa K; Munekage E; Iwabu J; Munekage M; Uemura S; Tsujii S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
In Vivo; 2018; 32(5):1211-1216. PubMed ID: 30150446
[TBL] [Abstract][Full Text] [Related]
44. The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video).
Ota K; Takeuchi T; Kodama K; Ozaki H; Harada S; Kojima Y; Nouda S; Goto M; Higuchi K
Intern Med; 2018 Feb; 57(3):343-344. PubMed ID: 29093427
[TBL] [Abstract][Full Text] [Related]
45. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
[TBL] [Abstract][Full Text] [Related]
47. Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.
Kitamura S; Tanahashi T; Aoyagi E; Nakagawa T; Okamoto K; Kimura T; Miyamoto H; Mitsui Y; Rokutan K; Muguruma N; Takayama T
Oncology; 2017; 93(2):127-135. PubMed ID: 28511180
[TBL] [Abstract][Full Text] [Related]
48. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Blum M; Suzuki A; Ajani JA
Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
[TBL] [Abstract][Full Text] [Related]
49. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
50. [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Hara A; Tokuhara T; Takahashi Y; Izumi N; Iwamoto S; Satake K
Gan To Kagaku Ryoho; 2004 Apr; 31(4):601-4. PubMed ID: 15114708
[TBL] [Abstract][Full Text] [Related]
51. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
[TBL] [Abstract][Full Text] [Related]
52. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
[TBL] [Abstract][Full Text] [Related]
53. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
Tsukuda M; Kida A; Fujii M; Kono N; Yoshihara T; Hasegawa Y; Sugita M;
Br J Cancer; 2005 Oct; 93(8):884-9. PubMed ID: 16189518
[TBL] [Abstract][Full Text] [Related]
54. Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy.
Yonemori K; Shimada Y; Goto A; Ura T; Arai T; Hamaguchi T; Muro K; Yamada Y; Shirao K
Gastric Cancer; 2004; 7(4):204-10. PubMed ID: 15616768
[TBL] [Abstract][Full Text] [Related]
55. [A multicenter clinical study for the comparison of S-1 versus capecitabine in the treatment of advanced breast cancer].
Li Y; Jiang D; Wu YY; Li LL; Cui YZ; Dong Q
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):607-612. PubMed ID: 28835084
[No Abstract] [Full Text] [Related]
56. [Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
Ohtsu A
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():52-6. PubMed ID: 16897972
[TBL] [Abstract][Full Text] [Related]
57. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
58. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
[TBL] [Abstract][Full Text] [Related]
59. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
[TBL] [Abstract][Full Text] [Related]
60. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
